Table 3 Outcome by risk groups . Risk... | American Society of Hematology

Table 3

Outcome by risk groups

	Risk group			Log-rank P value
	Low	Intermediate	High	Low vs intermediate	Low vs high	Intermediate vs high
n	51	55	29
Event-free survival, year 3 estimate*	72.4% ± 15%	56.5% ± 15%	32.6% ± 18%	.103	< .001	< .001
Overall survival, year 3 estimate	92.1% ± 8%	77.2% ± 12%	51.3% ± 19%	.089	< .001	.001
TMD-related mortality, year 3 estimate	2% ± 4%	0% ± 0%	45.0% ± 18%	.303	< .001	< .001

	Risk group			Log-rank P value
	Low	Intermediate	High	Low vs intermediate	Low vs high	Intermediate vs high
n	51	55	29
Event-free survival, year 3 estimate*	72.4% ± 15%	56.5% ± 15%	32.6% ± 18%	.103	< .001	< .001
Overall survival, year 3 estimate	92.1% ± 8%	77.2% ± 12%	51.3% ± 19%	.089	< .001	.001
TMD-related mortality, year 3 estimate	2% ± 4%	0% ± 0%	45.0% ± 18%	.303	< .001	< .001

TMD indicates transient myeloproliferative disorder.

The development of AML is considered an event.